Fig. 5: Pre- and post-test CIN3+ risk after applying different triage strategies. | British Journal of Cancer

Fig. 5: Pre- and post-test CIN3+ risk after applying different triage strategies.

From: The triage role of cytological DNA methylation in women with non-16/18, specifically genotyping high-risk HPV infection

Fig. 5

Pre- and post-test CIN3+ risk for different diagnostic methods: a LBC alone, b hrHPV genotyping alone, c CISCER alone, d LBC and hrHPV genotyping, e LBC and CISCER, and f hrHPV genotyping and CISCER. ASCUS+ classified as atypical squamous cells of undetermined significance or worse; CISCER− ΔCt PAX1 > 6.6 and ΔCt JAM3 > 10.0; CISCER+ ΔCt PAX1 ≤ 6.6 or ΔCt JAM3 ≤ 10.0; HPV33/35+ HPV33(+) or HPV35(+); HPV33/35− with at least one type of infection among HPV31, 39, 45, 51, 52, 56, 58, 59, 66, and 68; NILM no intraepithelial lesions or malignancy; OR odds ratio. Colours green, low CIN3+ risk; orange, intermediate CIN3+ risk; red high CIN3+ risk.

Back to article page